globenewswire news

Vistin Pharma ASA: Minutes from the annual general meeting 2026

2026-05-20T12:30:00Z

Oslo, Norway, 20 May 2026

Vistin Pharma ASA (OSE: VISTN), please find attached the minutes from the annual general meeting held today, on the 20 May 2026.

Attachment

Minutes from AGM Vistin Pharma ASA_20_May_2026

Articles

Nanobiotix Announces Launch of Global Follow-On Offering

2026-05-20T22:19:00Z

PARIS and CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to...

Nanobiotix Announces Launch of Global Follow-On Offering

2026-05-20T22:19:00Z

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-05-20T21:30:00Z

WALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today...

Johns Hopkins Health Plans Awards $60,000 to Maryland and Virginia Organizations

2026-05-20T20:42:03Z

Corporate Giving Program Supports Nonprofits Addressing Food Insecurity, Healthy Aging and Child Advocacy

Strongest Phentermine Alternatives 2026: What OTC Options Are Commonly Compared to Phentermine? PhenQ Formulation Assessment Using the SCALE-9 Evaluation Model

2026-05-20T20:31:51Z

PhenQ Editorial Report: OTC appetite suppressants, natural weight loss pills, prescription vs OTC standards, and a 9-point consumer verification framework for evaluating real-world effectiveness.

Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations

2026-05-20T20:30:00Z

In SELVA Phase 3 study, 100% of participants (13/13) aged 6–11 years were rated as “Much Improved” (+2) or “Very Much Improved” (+3) on the Microcystic Lymphatic Malformation Investigator Global...

Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026

2026-05-20T20:30:00Z

NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and...

CVRx to Present at the William Blair 46th Annual Growth Stock Conference

2026-05-20T20:30:00Z

MINNEAPOLIS, May 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular...

Information on the total number of voting rights and shares

2026-05-20T20:30:00Z

REGULATED INFORMATION

LeMaitre to Participate at Upcoming Investor Conferences in June

2026-05-20T20:25:14Z

BURLINGTON, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in two upcoming investor conferences in June.

BioAdaptives Launches MyndSystem™ Website — The First Supplement Platform Designed to Support Both Daytime Cognitive Performance and Overnight Brain Recovery

2026-05-20T20:15:53Z

Perform. Repair. Repeat. — A stimulant-free, dual-phase platform built on the principle that cognitive excellence depends as much on what the brain does overnight as on what it achieves during...

Dentsply Sirona to Participate in the 2026 Stifel Jaws & Paws Conference

2026-05-20T20:15:00Z

CHARLOTTE, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the 2026 Stifel Jaws...

Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update

2026-05-20T20:10:00Z

Year-over-year revenue increased 70%, reflecting contribution from Vivos’ acquisition of The Sleep Center of Nevada

Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference

2026-05-20T20:05:00Z

SUNNYVALE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions,...

Nyxoah Welcomes the Flemish Investors Federation (VFB) at LégiaPark following Q1 2026 Results and U.S. Commercial Momentum

2026-05-20T20:05:00Z

Nyxoah Welcomes the Flemish Investors Federation (VFB) at LégiaPark following Q1 2026 Results and U.S. Commercial Momentum

Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis

2026-05-20T20:05:00Z

Virtual webinar to be held on Wednesday, May 27 at 11:00 AM ET

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

2026-05-20T20:05:00Z

BOSTON and SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of...

Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities

2026-05-20T20:05:00Z

MIAMI, May 20, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that...

Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress

2026-05-20T20:05:00Z

Conference call and webcast to discuss results to be held on June 22, 2026 at 8 a.m. ET

20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress

2026-05-20T20:05:00Z

State-Funded Firefighter Cancer Screening Programs Expected to Drive Meaningful Revenue Growth Beginning in Q2 2026

Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

2026-05-20T20:01:00Z

SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one...